Business context and reporting period
This summary covers the unaudited quarter ended March 31, 2014. The filing identifies the registrant as Rexahn Pharmaceuticals, Inc., a development-stage oncology biopharmaceutical company—not Opus Genetics, Inc. This conflicts with the request metadata and should be verified.
Rexahn reported no product revenue. Its pipeline included one Phase II candidate, two Phase I candidates and preclinical programs. The company stated it expected continued losses while advancing development.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.77 million | $1.91 million |
| Operating loss | $2.77 million | $1.91 million |
| Net loss | $14.60 million | $1.53 million |
| Basic and diluted loss per share | $0.09 | $0.01 |
| Cash used in operating activities | $2.58 million | $1.55 million |
Q1 2014 net loss included an $11.66 million noncash unrealized loss from revaluing warrant liabilities, compared with a $369,000 unrealized gain in Q1 2013. Excluding that fair-value volatility, the quarter’s operating loss was $2.77 million. Research and development expense rose 130% to $1.27 million, primarily as Archexin and RX-3117 entered clinical trials. General and administrative expense increased 17% to $1.41 million; patent fees declined 47% to $72,000. Interest income was $32,000. Profit margins are not meaningful because the company had no revenue.
At March 31, cash and cash equivalents were $40.07 million, marketable securities $100,000, and restricted cash $164,000. Total current assets were $40.90 million; total liabilities were $13.09 million, including $11.29 million of warrant liabilities. No long-term debt balance was reported. Stockholders’ equity was $28.03 million. The company raised $18.63 million net in a January offering and received $5.23 million from warrant exercises and $70,000 from option exercises; financing cash flow was $23.93 million.
Changes, outlook and risks
- Management said available cash, restricted cash and marketable securities would fund minimum planned operating needs for at least 24 months, assuming prioritization of selected programs. It also said additional capital would be needed to continue development, with no assurance it could be raised on acceptable terms.
- For the next 12 months, management estimated minimum spending of $2.1 million on Archexin, $2.9 million on RX-3117, $1.4 million on Supinoxin, $3.3 million on preclinical pipeline and other R&D, and $3.8 million on corporate expenses. These are estimates, not earnings guidance.
- Archexin began a Phase IIa trial in metastatic renal cell carcinoma in January 2014; management expected to complete the initial safety component in Q4 2014 and estimated trial costs at about $5.0 million. RX-3117 began a Phase Ib solid-tumor trial in January; estimated costs were about $5.1 million. Supinoxin’s Phase I trial continued, with the maximum tolerated dose not yet reached.
- Teva had declined its option to license RX-3117 in 2013, terminating the related agreement. The remaining restricted funds were designated for unbilled expenses. Management cited clinical-development, regulatory-approval, financing, collaboration, intellectual-property and third-party research/manufacturing risks; trial timing and costs were uncertain.
- Research and development vendor agreements had estimated remaining costs of approximately $5.28 million ($26.21 million estimated total contract value less $20.93 million paid since inception); agreements were generally terminable with notice. Other disclosed commitments included future office rent of $847,000 through June 2019 and a $1.0 million KRICT milestone payable only upon a specified marketing approval, not achieved by quarter-end.
- Warrant liabilities were Level 3 fair-value measurements using significant assumptions, including a 5% estimated probability of a fundamental transaction. The resulting valuation produced substantial noncash earnings volatility and potential dilution. After quarter-end, holders exercised warrants for $718,750, and the company issued 1.25 million shares.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the 24-month liquidity assertion against planned trial spending, future financing needs and the stated possibility of reducing R&D if capital is unavailable.
- Assess warrant-liability valuation assumptions and outstanding potential dilution; the filing reported 18.92 million warrants and 10.25 million options outstanding at March 31, 2014.
- Check clinical-trial progress, spending and milestones against management’s estimates and timelines; outcomes, approval timing and future cash inflows were uncertain.
- Note a disclosure inconsistency: the MD&A describes Q1 2013 cash used in operations with a sentence that appears to label it as Q1 2014; the cash-flow statement reports $1.55 million for Q1 2013.